Lipidor Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Lipidor ha un patrimonio netto totale di SEK16.3M e un debito totale di SEK0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente SEK24.3M e SEK8.0M.

Informazioni chiave

Rapporto debito/patrimonio netto

SEK 0

Debito

Indice di copertura degli interessi	n/a
Contanti	SEK 22.75m
Patrimonio netto	SEK 16.29m
Totale passività	SEK 7.98m
Totale attività	SEK 24.27m

Aggiornamenti recenti sulla salute finanziaria

Here's Why We're Not At All Concerned With Lipidor's (STO:LIPI) Cash Burn Situation

May 13

Companies Like Lipidor (STO:LIPI) Are In A Position To Invest In Growth

Jan 29

Recent updates

We're Hopeful That Lipidor (STO:LIPI) Will Use Its Cash Wisely

Sep 04

Lipidor (STO:LIPI) Is In A Strong Position To Grow Its Business

Feb 24

We Think Lipidor (STO:LIPI) Can Afford To Drive Business Growth

Sep 15

Here's Why We're Not At All Concerned With Lipidor's (STO:LIPI) Cash Burn Situation

May 13

Companies Like Lipidor (STO:LIPI) Are In A Position To Invest In Growth

Jan 29

Need To Know: Lipidor AB (publ) (STO:LIPI) Insiders Have Been Selling Shares

Dec 07

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( SEK23.8M ) di LIPI superano le sue passività a breve termine ( SEK8.0M ).

Passività a lungo termine: LIPI non ha passività a lungo termine.

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: LIPI è esente da debiti.

Riduzione del debito: LIPI non aveva debiti 5 anni fa.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: LIPI ha una pista di cassa sufficiente per più di un anno in base al suo attuale flusso di cassa libero.

Previsione Cash Runway: LIPI ha una liquidità sufficiente per 1.6 anni se il flusso di cassa libero continua a ridursi ai tassi storici del 16.2 % ogni anno.

Lipidor Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

We're Hopeful That Lipidor (STO:LIPI) Will Use Its Cash Wisely

Lipidor Ordinary Shares to Be Deleted from OTC Equity

Lipidor (STO:LIPI) Is In A Strong Position To Grow Its Business

We Think Lipidor (STO:LIPI) Can Afford To Drive Business Growth

Here's Why We're Not At All Concerned With Lipidor's (STO:LIPI) Cash Burn Situation

Companies Like Lipidor (STO:LIPI) Are In A Position To Invest In Growth

Recent updates

New major risk - Market cap size

Lipidor AB (publ) Announces First Patient Enrolled in Phase III Study of AKP02G2 for Topical Treatment of Psoriasis

New major risk - Shareholder dilution

Lipidor AB (publ) to Report Fiscal Year 2024 Results on Feb 28, 2025

Lipidor AB (publ) Announces That Clinical Trial Material for Psoriasis Candidate AKP02G2 Has Been Releases According to Plan

First quarter 2024 earnings released: EPS: kr0.011 (vs kr0.014 in 1Q 2023)

Lipidor AB (publ) to Report Fiscal Year 2023 Final Results on May 15, 2024

Lipidor AB (publ) Announces Approval for Start of Phase III Clinical Trial of Psoriasis Candidate AKP02G2

Full year 2023 earnings released: kr0.40 loss per share (vs kr1.43 loss in FY 2022)

Lipidor Applies to the Indian Medical Products Agency to Start A Phase III study of AKP02G2

Lipidor AB (publ), Annual General Meeting, Jun 05, 2024

Lipidor AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Lipidor AB (publ) Files New Patent Application with the European Patent Office

Second quarter 2023 earnings released: kr0.13 loss per share (vs kr0.30 loss in 2Q 2022)

Insufficient new directors

Lipidor AB (Publ) Confirms Clinical Plan for New Version of Akp02

Full year 2022 earnings released: kr1.43 loss per share (vs kr0.75 loss in FY 2021)

Lipidor AB (publ), Annual General Meeting, Jun 08, 2023

Lipidor AB (publ) to Report Nine Months, 2023 Results on Nov 22, 2023

Lipidor AB (Publ) Provides Update Following Outcome of Phase Iii Study of Psoriasis Candidate Akp02

Lipidor AB (publ) Announces Results from the Its Clinical Phase III Study of AKP02 for Psoriasis

Lipidor Updates on Phase III Clinical Study of Psoriasis Candidate AKP02

We're Hopeful That Lipidor (STO:LIPI) Will Use Its Cash Wisely

Second quarter 2022 earnings released: kr0.30 loss per share (vs kr0.26 loss in 2Q 2021)

Lipidor AB (Publ) Appoints Charlotta Ekman as Chief Financial Officer, with Effect from October 1, 2022

Lipidor AB (Publ) Announces All Patients in Lipidor's Phase III Study with Psoriasis Candidate Akp02 Have Completed Treatment

Lipidor AB (publ) Announces Last Patient Has Been Enrolled in the Ongoing Phase III Study of AKP02 Against Mild to Moderate Psoriasis

Lipidor Ordinary Shares to Be Deleted from OTC Equity

Lipidor Updates on Phase III Study of AKP02 in Treatment of Psoriasis

Price target decreased to kr14.50

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Consensus EPS estimates fall by 40%

Price target decreased to kr14.50

Independent Chairman of the Board recently bought kr111k worth of stock

Independent Chairman of the Board recently bought kr111k worth of stock

Lipidor (STO:LIPI) Is In A Strong Position To Grow Its Business

Lipidor Announces Enrolment of First Patients in a Phase III Study on AKP02 for Treatment of Psoriasis

Lipidor AB (Publ) Expands Clinical Program, Announces Investment in New Drug Development Project Against Acne Vulgaris

No longer forecast to breakeven

Chief Executive Officer exercised options to buy kr3.7m worth of stock.

Lipidor AB (publ) Announces Approval to Start Phase III Clinical Study of Drug Candidate Akp02 for Treatment of Psoriasis

We Think Lipidor (STO:LIPI) Can Afford To Drive Business Growth

Here's Why We're Not At All Concerned With Lipidor's (STO:LIPI) Cash Burn Situation

New 90-day low: kr10.93

Companies Like Lipidor (STO:LIPI) Are In A Position To Invest In Growth

New 90-day low: kr11.98

Cannassure Therapeutics Ltd., Enters into Exclusive Licensing Agreement Regarding Topical Medical Cannabis Products Based on Lipidor's Akvano Technology

Lipidor AB and Cannassure Therapeutics Ltd Enter Exclusive Licensing Agreement Regarding Topical Medical Cannabis Products Based on Lipidor's Akvano® Technology

Lipidor AB (publ) to Report Q3, 2021 Results on Nov 17, 2021

Lipidor Signs Cooperation Agreement with Aurena Laboratories AB to Offer Licensees the Opportunity for GMP Production

Need To Know: Lipidor AB (publ) (STO:LIPI) Insiders Have Been Selling Shares

Lipidor AB (Publ) Announces Nomination Committee

Lipidor AB (publ) to Report Q1, 2021 Results on May 06, 2021

Lipidor Announces Positive Outcome of Feasibility Study for Development of Topical Medical Cannabis Products Based on the Company's Akvano® Technology

New 90-day low: kr12.55

First half earnings released

Lipidor AB (publ) to Report Q4, 2020 Results on Feb 09, 2021

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane